A closer look at the technologies used by PellePharm
PellePharm
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Mission St Ste 1950, San Francisco, ...Phone Number
(510) 502-6144Website
www.pellepharm.comRevenue
$16.4 MillionIndustry
About PellePharm
PellePharm is a biotechnology company dedicated to addressing rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas, through precision medicine. The company focuses on developing patidegib, an investigational topical treatment aimed at reducing tumor burden in affected patients. Collaborating with organizations like the Gorlin Syndrome Alliance, PellePharm strives to advance research and transform the lives of individuals impacted by these conditions. With a commitment to patient care, PellePharm is working towards providing effective therapies in a field with currently no FDA-approved options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to PellePharm
Compare insights from companies similar to PellePharm, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PellePharm
$16.4M
11-50
Private
$99.8M
2012
N/A
PellePharm Tech Stack
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PellePharm
Sign Up For FreeTo access detailed company insights
PellePharm is a biotechnology company dedicated to addressing rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas, through precision medicine. The company focuses on developing patidegib, an investigational topical treatment aimed at reducing tumor burden in affected patients. Collaborating with organizations like t... Read More
